13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Dense Genotyping of Immune-Related Loci Identifies Variants Associated with Clearance of HPV among HIV-Positive Women in the HIV Epidemiology Research Study (HERS)

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Persistent high-risk human papillomavirus (HR-HPV) is a necessary and causal factor of cervical cancer. Most women naturally clear HPV infections; however, the biological mechanisms related to HPV pathogenesis have not been clearly elucidated. Host genetic factors that specifically regulate immune response could play an important role. All HIV-positive women in the HIV Epidemiology Research Study (HERS) with a HR-HPV infection and at least one follow-up biannual visit were included in the study. Cervicovaginal lavage samples were tested for HPV using type-specific HPV hybridization assays. Type-specific HPV clearance was defined as two consecutive HPV-negative tests after a positive test. DNA from participants was genotyped for 196,524 variants within 186 known immune related loci using the custom ImmunoChip microarray. To assess the influence of each single-nucleotide polymorphism (SNP) with HR-HPV clearance, the Cox proportional hazards model with the Wei-Lin-Weissfeld approach was used, adjusting for CD4+ count, low risk HPV (LR-HPV) co-infection, and relevant confounders. Three analytical models were performed: race-specific (African Americans (n = 258), European Americans (n = 87), Hispanics (n = 55), race-adjusted combined analysis, and meta-analysis of pooled independent race-specific analyses. Women were followed for a median time of 1,617 days. Overall, three SNPs (rs1112085, rs11102637, and rs12030900) in the MAGI-3 gene and one SNP (rs8031627) in the SMAD3 gene were associated with HR-HPV clearance (p<10 −6). A variant (rs1633038) in HLA-G were also significantly associated in African American. Results from this study support associations of immune-related genes, having potential biological mechanism, with differential cervical HR-HPV infection outcomes.

          Related collections

          Most cited references35

          • Record: found
          • Abstract: found
          • Article: not found

          The causal relation between human papillomavirus and cervical cancer.

          The causal role of human papillomavirus infections in cervical cancer has been documented beyond reasonable doubt. The association is present in virtually all cervical cancer cases worldwide. It is the right time for medical societies and public health regulators to consider this evidence and to define its preventive and clinical implications. A comprehensive review of key studies and results is presented.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Transcriptional control by the TGF-beta/Smad signaling system.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Immune responses to human papillomavirus.

              The immune system uses innate and adaptive immunity to recognize and combat foreign agents that invade the body, but these methods are sometimes ineffective against human papillomavirus (HPV). HPV has several mechanisms for avoiding the immune system. HPV infects, and multiplies in keratinocytes, which are distant from immune centers and have a naturally short lifespan. The naturally short life cycle of the keratinocyte circumvents the need for the virus to destroy the cell, which would trigger inflammation and immune response. In addition, HPV downregulates the expression of interferon genes. Despite viral immune evasion, the immune system effectively repels most HPV infections, and is associated with strong localized cell mediated immune responses. New prophylactic L1 virus-like protein vaccines for HPV 16 and 18 and HPV 6, 11, 16, and 18 are in phase 3 trials. Available data suggests that these vaccines are safe, produce high levels of antibodies, and are effective at preventing HPV infection.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS One
                PLoS ONE
                plos
                plosone
                PLoS ONE
                Public Library of Science (San Francisco, USA )
                1932-6203
                2014
                11 June 2014
                18 June 2014
                : 9
                : 6
                : e99109
                Affiliations
                [1 ]Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America
                [2 ]Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
                [3 ]Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
                [4 ]Department of Obstetrics and Gynecology and Medicine, Brown University, Providence, Rhode Island, United States of America
                [5 ]Mount Sinai School of Medicine, New York, New York, United States of America
                [6 ]Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States of America
                [7 ]School of Medicine, Wayne State University, Detroit, Michigan, United States of America
                University of Rome Tor Vergata, Italy
                Author notes

                Competing Interests: The authors have declared that no competing interests exist.

                Conceived and designed the experiments: SLS CCK AMR SC RSK KVS JDS DJJ SS. Performed the experiments: SLS SS. Analyzed the data: SLS HWW SS. Contributed reagents/materials/analysis tools: HWW CCK DJJ SS. Wrote the paper: SLS SS. Reviewed and edited the manuscript: HWW CCK AMR SC RSK KVS JDS DJJ.

                Article
                PONE-D-14-05335
                10.1371/journal.pone.0099109
                4053382
                24918582
                70d3b21d-3dfc-4aca-add7-e328fd2c3cda
                Copyright @ 2014

                This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

                History
                : 4 February 2014
                : 10 May 2014
                Page count
                Pages: 8
                Funding
                Genotyping efforts were supported by the Pilot Project Award (PI: Sadeep Shrestha) from the Johns Hopkins Cervical Cancer SPORE (2P50CA098252 PI: TC Wu). The work was supported in part by the NIH Cancer Prevention and Control Training Program (R25CA47888 – fellowship of Staci Sudenga). The HIV Epidemiology Research Study (HERS) was funded through Centers for Disease Control and Prevention cooperative agreements U64/CCU106795, U64/CCU206798, U64/CCU306802, and U64/CCU506831. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
                Categories
                Research Article
                Biology and Life Sciences
                Genetics
                Immunology
                Population Biology
                Medicine and Health Sciences
                Epidemiology
                Genetic Epidemiology
                Infectious Disease Epidemiology

                Uncategorized
                Uncategorized

                Comments

                Comment on this article